- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07663305
Evaluation of a Mobile Menopause Application (EMMA)
This study examines whether a digital app can help women manage symptoms of menopause. A total of 426 women with medically confirmed menopausal symptoms are randomly assigned to either use the app in addition to their usual medical care for 24 weeks, or to continue with usual care alone. The app provides evidence-based content and exercises for multimodal menopause management. Participants are followed up over 24 weeks, with the primary outcome assessed at 12 weeks. The main goal is to evaluate whether the app improves menopause-specific quality of life.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Hanover, Deutschland
- Rekrutierung
- Medicoles
-
Hauptermittler:
- Elisabeth Siegmund-Schultze, Dr. med.
-
Kontakt:
- Elisabeth Siegmund-Schultze, Dr. med.
- E-Mail: studienleitung@wechseljahr-studie.de
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Legal capacity
- Ability to provide informed consent
- Residency in Germany
- Female gender
- Age ≥18 years
- Medically confirmed menopausal or other perimenopausal disorder (N95.1)
- Ownership of a smartphone and ability to use it
- Internet access for app usage and questionnaire completion
- Email address for registration
- Willingness to complete questionnaires online
- Motivation for regular app usage
- Sufficient proficiency in the German language
- MRS II ≥ 9
- Absence of exclusion criteria
Exclusion Criteria:
- Pregnancy or breastfeeding during the study period
- Current hormonal replacement therapy (HRT), initiation of HRT within eight weeks prior to study start and/or planned start of HRT during the study period
- Changes in treatment with psychotropic medication within eight weeks prior to study start and/or planned during the study period
- Start of psychotherapy within eight weeks prior to study start and/or planned during the study period
- Start of a rehabilitation program within eight weeks prior to study start and/or planned during the study period
- Surgery performed within eight weeks prior to study start and/or planned during the study period
- Previous or current access to the Endo-App or other comparable digital health applications, or current active prescription
- Current participation in other clinical studies
- Failure to meet the inclusion criteria
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Kein Eingriff: Control Group
The control group has access to care-as-usual only. |
|
|
Experimental: Intervention Group
The intervention group has access to the menopause app and its functions in addition to care-as-usual. |
The menopause app facilitates the implementation of multimodal self-management strategies in the daily routines of individuals with a menopausal disorder, through tools such as a symptom diary and guided interactive exercises. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Menopause-specific quality of life
Zeitfenster: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the Menopause-specific Quality of Life Questionnaire (MENQOL) |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Menopause-specific symptom severity
Zeitfenster: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the Menopause Rating Scale (MRS II) |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
|
Daily interference due to hot flashes
Zeitfenster: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the Hot Flash Related Daily Interference Scale (HFRDIS) |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
|
Menopause-specific impairment in daily activities
Zeitfenster: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the Activity Impairment domain of the Work Productivity and Activity Impairment-Menopause questionnaire (WPAI-Menopause) |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
|
Patient activation
Zeitfenster: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the Patient Activation Measure 13 (PAM-13) |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Menopause-specific quality of life
Zeitfenster: Changes between time point T0 (baseline) and T4 (24 weeks after baseline)
|
Assessed with the Menopause-specific Quality of Life Questionnaire (MENQOL) |
Changes between time point T0 (baseline) and T4 (24 weeks after baseline)
|
|
Menopause-related absenteeism
Zeitfenster: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the absenteeism domain score of the Work Productivity and Activity Impairment-Menopause questionnaire (WPAI-Menopause). |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
|
Menopause-related presenteeism
Zeitfenster: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the presenteeism domain score of the Work Productivity and Activity Impairment-Menopause questionnaire (WPAI-Menopause). |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
|
Menopause-related work productivity loss
Zeitfenster: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the work productivity loss domain score of the Work Productivity and Activity Impairment-Menopause questionnaire (WPAI-Menopause). |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- RCT_EMMA
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .